Granted Patent
B2
US 12,186,424 · App. 17/227,877 · Granted Jan 7, 2025
Compositions and methods for treating pterygium recurrence
Assignee:
Cloudbreak Therapeutics, LLC
A61K9/0048A61F9/00A61F9/0017A61K9/0051A61K9/06A61K9/08A61K9/10A61K9/107A61K31/404A61K31/407A61K31/496A61K31/505A61K45/06A61K47/26A61P27/00A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.
Claims (6)
1. A method for inducing regression of a pterygium from the central cornea of an affected eye without surgically excising the pterygium, comprising administering to the affected eye of a subject in need of such treatment a therapeutically effective amount of a combination therapy of (1) 5-fluorouracil and (2) nintedanib.
2. The method of claim 1 , wherein the combination therapy is administered to the affected eye in the form of a topical ocular formulation or ocular implant.
3. The method of claim 2 , wherein the topical ocular formulation is a solution or suspension.
4. A method for inhibiting, reducing, or regressing neovascularization in an eye affected with pterygium in a subject in need of such treatment, without surgically excising the pterygium, comprising administering to the affected eye of the subject in need thereof a therapeutically effective amount of a combination therapy of (1) 5-fluorouracil and (2) nintedanib.
5. The method of claim 4 , wherein the combination therapy is administered to the affected eye in the form of a topical ocular formulation or ocular implant.
6. The method of claim 5 , wherein the topical ocular formulation is a solution or suspension.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2021
From: NI, JINSONG
To: CLOUDBREAK THERAPEUTICS, LLC
Reel/Frame 055998/0533 →
Continuity (8)
Continuation
PCTUS2016035726
· Jun 3, 2016
Provisional Application
62186660
· Jun 30, 2015
Provisional Application
62172063
· Jun 6, 2015
References Cited (233)
US 8747852B1
· Pham
· 2014
[cited by applicant]
US 9980901B2
· Ni
· 2018
[cited by applicant]
US 9987223B2
· Ni
· 2018
[cited by applicant]
US 20060052286A1
· Garen et al.
· 2006
[cited by applicant]
US 20080003219A1
· Peyman
· 2008
[cited by applicant]
US 20100185564A1
· King et al.
· 2010
[cited by applicant]
US 20130012531A1
· King
· 2013
[cited by applicant]
US 20130316006A1
· Popov et al.
· 2013
[cited by applicant]
US 20140186336A1
· Pham
· 2014
[cited by applicant]
US 20140235678A1
· Böttger et al.
· 2014
[cited by applicant]
US 20150037422A1
· Kaplan et al.
· 2015
[cited by applicant]
US 20150141448A1
· Bottger et al.
· 2015
[cited by applicant]
US 20150164790A1
· Bottger et al.
· 2015
[cited by applicant]
US 20150258120A1
· Zarnitsyn et al.
· 2015
[cited by applicant]
US 20160038760A1
· Hamrah et al.
· 2016
[cited by applicant]
US 20220331310A1
· Ni
· 2022
[cited by applicant]
CA 2989121
· 2016
[cited by applicant]
CN 1247469
· 2000
[cited by applicant]
CN 100455568
· 2009
[cited by applicant]
CN 102018686
· 2011
[cited by applicant]
CN 103212075
· 2013
[cited by applicant]
CN 103889399
· 2014
[cited by applicant]
CN 103998431
· 2014
[cited by applicant]
CN 104379128
· 2015
[cited by applicant]
CN 104379129
· 2015
[cited by applicant]
CN 104379133
· 2015
[cited by applicant]
CN 104448300
· 2015
[cited by applicant]
CN 103732623
· 2017
[cited by applicant]
CN 107708664
· 2018
[cited by applicant]
CN 110072849
· 2019
[cited by applicant]
CN 108135737
· 2021
[cited by applicant]
EP 3463315
· 2023
[cited by applicant]
JP 2014518064
· 2014
[cited by applicant]
JP 2016501849
· 2016
[cited by applicant]
JP 2016040313
· 2016
[cited by applicant]
KR 20150083117
· 2015
[cited by applicant]
RU 2351298
· 2009
[cited by applicant]
WO WO2001002369
· 2001
[cited by applicant]
WO WO2007012974
· 2007
[cited by applicant]
WO WO2007038453
· 2007
[cited by applicant]
WO WO2008122858
· 2008
[cited by applicant]
WO WO2009147212
· 2009
[cited by applicant]
WO WO2009147220
· 2009
[cited by applicant]
WO WO2012167143
· 2012
[cited by applicant]
WO WO2013105895
· 2013
[cited by applicant]
WO WO2013188268
· 2013
[cited by applicant]
WO WO2013188283
· 2013
[cited by applicant]
WO WO2014074823
· 2014
[cited by applicant]
WO WO2014078655
· 2014
[cited by applicant]
WO WO2014204791
· 2014
[cited by applicant]
WO WO2015108787
· 2015
[cited by applicant]
WO WO2016029191
· 2016
[cited by applicant]
WO WO2016209555
· 2016
[cited by applicant]
WO WO2017210130
· 2017
[cited by applicant]
WO WO2018022437
· 2018
[cited by applicant]
WO WO2018054077
· 2018
[cited by applicant]
WO WO2018064354
· 2018
[cited by applicant]
WO WO2019226864
· 2019
[cited by applicant]
WO WO2020103958
· 2020
[cited by applicant]
WO WO2021168218
· 2021
[cited by applicant]
WO WO2023103835
· 2023
[cited by applicant]
Chui et al., “Pterygium Pathogenesis, Actinic Damage, and Recurrence,” Techniques and Technologies for Surgical Success, 2012, pp. 1-26.
[cited by applicant]
Fotouhi et al., “Prevalence and risk factors of pterygium and pinguecula: the Tehran Eye Study,” Nature, 2009, 1125-1129.
[cited by applicant]
Jaros et al., “Diagnostic and Surgical Techniques,” Survey of Ophthalmology, Jul. 1988, 33(1), 9 pages.
[cited by applicant]
Mimura et al., “Severity and Determinants of Pinguecula in a Hospital-Based Population,” Eye & Contact Lens: Science & Clinical Practice, 2011, 37:31-35.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/050150, dated Mar. 15, 2022, 7 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2020/050150, dated Mar. 26, 2021, 8 pages.
[cited by applicant]
Kaufman et al., “Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology,” Ophthalmology, Jan. 2013, 120(1):201-208.
[cited by applicant]
Schiffman et al., “Reliability and validity of the Ocular Surface Disease Index,” Arch Ophthalmol., May 2000, 118(5):615-621.
[cited by applicant]
USPTO Patent Trial and Appeal Board, “Decision on Appeal,” Appeal No. IPR2020-01438, U.S. Pat. No. 10,149,820 B2, dated Feb. 15, 2022, 79 pages.
[cited by applicant]
Kinoshita et al., “Please Tell Me About Pterygium, Pseudopterygium, Ocular Cicatricial Pemphigoid,” New Opthamology, J. of the Eye, 2014, 31:8-9 (English translation).
[cited by applicant]
O'Connor et al., “Wound healing modulation in glaucoma filtration surgery-conventional practices and new perspectives: Antivascular endothelial growth factor and novel agents(Part II),” J. of Curent Glaucoma Prac., 2014…
[cited by applicant]
“Concise Description of Relevance of International Patent Application Publication No. WO 2007/038453 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,62…
[cited by applicant]
“Concise Description of Relevance of International Patent Application Publication No. WO 2013/188283 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,62…
[cited by applicant]
“Concise Description of Relevance of International Patent Application Publication No. WO 2016/209555 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,62…
[cited by applicant]
“Concise Description of Relevance of Roskoski, Biochemical and Biophysical Research Communications 356 (2007) 323-328 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Ap…
[cited by applicant]
“Concise Description of Relevance of Roth et al. J. Med. Chem. (2015) 58, 1053-1063 to Pending Claims of U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,620, dated Oct. 20,…
[cited by applicant]
“Third Party Pre-Issuance Submission Pursuant To 35 U.S.C. § 122(e) and 37 C.F.R. §1.290 for U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,620, dated Oct. 20, 2017, 3 pag…
[cited by applicant]
“Third-Party Submission Under 37 CFR 1.290 Concise Description of Relevance, for U.S. Appl. No. 15/474,620,” Third-Party Submission Under 37 CRF 1.290 in U.S. Appl. No. 15/474,620, dated Oct. 20, 2017, 4 pages.
[cited by applicant]
[No Author Listed], “Clinical Pharmacology and Biopharmaceutics Review(s),” Center for Drug Evaluation and Research, submitted by Boehringer Ingelheim, Inc. on May 2, 2014, 140 pages (Exhibit No. 1026).
[cited by applicant]
[No Author Listed], “EPAR Summary for the Public: Vargatef (nintedanib),” European Medicines Agency, C 2015, 3 pages (Exhibit No. 1013).
[cited by applicant]
[No Author Listed], “OFEV (nintedanib) FDA Label,” Boehringer Ingelheim Pharmaceuticals, Inc., © 2014, 18 pages (Exhibit No. 1012).
[cited by applicant]
[No Author Listed], “Standard Affidavit,” Internet Archive Standard Affidavit, 2020, 2 pages, retrieved from URL: https://archive.org/legal/affidavit/php, retrieved on Jul. 31, 2020 (Exhibit No. 1029).
[cited by applicant]
[No Author Listed], “Table of Contents,” IOVS, 2013, 54(1):1-24, retrieved from URL: https://web.archive.org/web/20131008205602/http:/www.iovs.org/content/54/1.toc, retrieved on Jul. 30, 2020 (Exhibit No. 1028).
[cited by applicant]
Affidavit of Elizabeth Rosenberg, dated Aug. 5, 2020, 22 pages (Exhibit No. 1030).
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
Al-Torbak, “Photodynamic Therapy with Verteporfin for Corneal Neovascularization, ” Middle East Afr. J. Opthalmol., Apr.-Jun. 2012, 19(2):185-189.
[cited by applicant]
Amoozgar et al., “A role for antimetabolites in glaucoma tube surgery: current evidence and future directions.”, Curr Opin Ophthalmol., 27(2): 164-9, 2016.
[cited by applicant]
Amparo et al., “Safety and Efficacy of the Multitargeted Receptor Kinase Inhibitor Pazopanib in the Treatment of Comeal Neovascularization,” Investigative Ophthalmology & Visual Science, Jan. 2013, 54(1):537-544.
[cited by applicant]
Amparo et al., “Safety and Efficacy of the Multitargeted Receptor Kinase Inhibitor Pazopanib in the Treatment of Comeal Neovascularization,” Investigative Ophthalmology & Visual Science, Jan. 2013, 54(1):537-544 (Exhibi…
[cited by applicant]
AVASTIN® Label, Revised Sep. 2011.
[cited by applicant]
Aversa et al., “Linifanib: current status and future potential in cancer therapy”, Expert Rev. Anticancer Ther. Early online, 1-11, 2015.
[cited by applicant]
Bayyoud et al., “Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells,” Current Eye Research, 2014, 39(2):149-154.
[cited by applicant]
Bhartiya et al., “The Need to maintain Intraocular Pressure over 24 Hours”, Journal of Current Glaucoma Practice, 6(3): 120-123, 2012.
[cited by applicant]
Brandão et al., “Update on Minimally Invasive Glaucoma Surgery (MIGS) and New Implants”, Journal of Ophthalmology, 12 pages, 2013.
[cited by applicant]
CAS Registry record for NINTEDANIB, retrieved from STN on Aug. 12, 2020.
[cited by applicant]
Chaudhary et al., “XEN Gel Implant: a new surgical approach in glaucoma”, Expert Review of Medical Devices, 15:1, 47-59, 2018.
[cited by applicant]
Chinese Office Action in Chinese Appln. No. 201680042858, dated Oct. 21, 2019, 12 pages (with English translation).
[cited by applicant]
Cox et al., “Doxycycline's Effect on Ocular Angiogenesis: an In Vivo Analysis,” Ophthalmology, Sep. 2010; 117(9):1782-91.
[cited by applicant]
Daniels et al., “Imatinib Treatment for Idiopathic Pulmonary Fibrosis Randomized Placebo-controlled Trial Results”, J Respir Crit Care Med vol. 181. pp 604-610, 2010.
[cited by applicant]
Davis et al., “Comprehensive analysis of kinase inhibitor selectivity,” Nautre Biotechnology, 2011, 29(11):1046-1051 (Exhibit No. 1016).
[cited by applicant]
Extended European Search Report in Application No. 16808064.6, dated Jan. 3, 2019, 8 pages.
[cited by applicant]
Fossarello et al., “Photodynamic Therapy of Corneal Neovascularization with Verteporfin,” Cornea, Jul. 1, 2003, 22(5):485-488.
[cited by applicant]
Fossarello et al., “Photodynamic Therapy of Pterygium With Verteporfin: A Preliminary Report,” Cornea, May 2004, 23(4): 330-338.
[cited by applicant]
Gedde et al., “Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-up”, Am J Ophthalmol., 153(5): 789-803, 2012.
[cited by applicant]
Gougis et al., “Clinical pharmacology of anti-angiogenic drugs in oncology,” Critical Reviews in Oncology / Hematology, 2017, 119:75-93 (Exhibit No. 1024).
[cited by applicant]
Gover-Proaktor et al., “Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells,” Leukemia & Lymphoma, 2018, 60:189-199…
[cited by applicant]
Hall et al., “Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC),” Transl Lung Cancer Res., Oct. 2015;4(5), 515-23.
[cited by applicant]
Hilberg et al., “BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy,” Cancer Res., Jun. 15, 2008; 68(12):4774-4782.
[cited by applicant]
Hojjat-Farsangi, “Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies”, Int. J. Mol. Sci., 15, 13768-13801, 2014.
[cited by applicant]
Hostettler et al., “Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis,” Respiratory research, 2014, 15:157.
[cited by applicant]
Hueber et al., “Photodynamic therapy for wound-healing modulation in pterygium surgery. A clinical pilot study,” Graefe's Arch Clin Exp Opthalmol, Apr. 2005, 243:942-946.
[cited by applicant]
Huu et al., “Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor In the posterior segment of the eye” Journal of Controlled Release, Feb. 28, 2015, 200:71-77.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US16/35726, mailed Dec. 21, 2017, 10 pages.
[cited by applicant]
International Search Report and Written Opinion in Application No. PCT/US17/34792, dated Oct. 25, 2017, 14 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US16/35726, mailed Sep. 1, 2016, 13 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US17/34795, dated Aug. 27, 2017, 10 pages.
[cited by applicant]
Inventor Declaration filed during the Prosecution of US Patent Application Publication No. 20130012531 to King et al., dated Sep. 2012, 3 pages (Exhibit No. 1020).
[cited by applicant]
Jovanovic et al., “The Effect of Topical Doxycycline on Corneal Neovascularization,” Current Eye Research, Feb. 1, 2014, 39(2):142-148.
[cited by applicant]
Kaplowitz et al., “Techniques and Outcomes of Minimally-Invasive Trabecular Ablation and Bypass Surgery”, Br J Ophthalmol., 98(5): 579-585, 2014.
[cited by applicant]
Kareem et al., The use of antimetabolites as adjunctive therapy in fhe surgical treatment of pterygium Clinical Ophthalmology, vol. 6 (Nov. 7, 2012), 6 pages.
[cited by applicant]
Katoh, “FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)”, International Journal of Molecular Medicine 38: 3-15, 2016.
[cited by applicant]
Kay et al., “Imatinib Mesylate Treatment of Nephrogenic Systemic Fibrosis”, ARTHRITIS & RHEUMATISM, vol. 58, No. 8, pp. 2543-2548, 2008.
[cited by applicant]
Kitagawa et al., “Activity-based kinase profiling of approved tyrosine kinase inhibitors”, Genes to Cells, 18, 110-122, 2013.
[cited by applicant]
Ko et al., “Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model,” Cornea, May 2013;32(5):689-695.
[cited by applicant]
Kria, “Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis,” Graefe's Arch for Clin. Exp. Ophthalmol., 1998, 236:702-708.
[cited by applicant]
Kria, “Immunohistochemical localization of basic fibroblast growth factro, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-a in the pterygium,” Acta Histochem, 1996, 98:195-201.
[cited by applicant]
Kumar et al., “Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors,” British Journal of Cancer, Oct. 2009; 101:1717-1723.
[cited by applicant]
Lee et al., “Effect of porcine chondrocyte-derived extracellular matrix on the pterygium in mouse model,” Graefes Arch Clin Exp Ophthalmol., Apr. 2014; 252(4):609-618.
[cited by applicant]
Lee et al., “Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis”, ASTR, 8 pages, 2015.
[cited by applicant]
Livezeanu et al., “Angiogenesis in the pathogenesis of pterygium”, Rom. J. Morph. Embryol, Jan. 2011, pp. 837-844.
[cited by applicant]
Lucentis® Label, Clinical Trial Date Dec. 2011.
[cited by applicant]
Maddula et al., “Horizons in Therapy for Corneal Angiogenesis,” Ophthalmology, Mar. 2011, 118(3):591-599.
[cited by applicant]
Manallack et al., “The significance of acid/base properties in drug discovery,” Chem. Soc. Rev., 2013, 42:485-496 (Exhibit No. 1018).
[cited by applicant]
Masoumpour et al., “Current and future techniques in wound healing modulation after glaucoma filtering surgeries,” The Open Ophthalmology Journal, 2016, 10(1):68-85.
[cited by applicant]
Memorandum from Deputy Commisioner from Patent Examination Policy to Patent Examining Corps, dated Apr. 5, 2018, 7 pages (Exhibit No. 1019).
[cited by applicant]
OFEV Capsules Approval Letter, Application No. 205832Orig1s000, 8 pages, Approval date Oct. 15, 2014.
[cited by applicant]
Ornitz et al., “The Fibroblast Growth Factor signaling pathway”, WIREs Dev Biol., vol. 4, 215-266, 2015.
[cited by applicant]
PCT International Publication No. WO 2007038453, published on Apr. 5, 2007, Peyman et al., 54 pages (Exhibit No. 1010).
[cited by applicant]
PCT International Publication No. WO 2016209555, published on Dec. 29, 2016, Nguyen et al., 42 pages (Exhibit No. 1006).
[cited by applicant]
Peng, “Vascular endothelial growth factor gene polymorphism and protein expression in pathogenesis of pterygium,” Br J Ophthalmol., 2013, 98:556-561.
[cited by applicant]
Perez-Santonja et al., “Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model,” Am J Ophthalmol., Oct. 2010, 150(4):519-528 (Exhibit No. 1…
[cited by applicant]
Perez-Santonja et al., “Inhibition of Corneal Neovascularization by Topical Bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an Animal Model,” Am J Ophthalmol., Oct. 2010;150(4):519-528.
[cited by applicant]
Pozarowska et al., “The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy”, Cent. Eur. J. Immunol., 41 (3): 311-316, 2016.
[cited by applicant]
Prosecution History of U.S. Pat. No. 10,149,820, filed on May 29, 2018, 132 pages (Exhibit No. 1002).
[cited by applicant]
Prosecution History of U.S. Pat. No. 10,154,994, filed on Sep. 11, 2017, 709 pages (Exhibit No. 1015).
[cited by applicant]
Prosecution History of U.S. Pat. No. 9,987,223, filed on Apr. 11, 2017, 562 pages (Exhibit No. 1025).
[cited by applicant]
Response to Office Action in U.S. Appl. No. 16/210,896, filed Apr. 10, 2020, 20 pages (Exhibit No. 1023).
[cited by applicant]
Roskoski Jr., “Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes,” Pharmacological Research, 2016, 103:26-48 (Exhibit No. 1017).
[cited by applicant]
Roskoski Jr., “Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor,” Biochem.Biophys. Res. Comm. (2007) 356:323-328.
[cited by applicant]
Roth et al. “Nintedanib: From Discovery to the Clinic” J. Med. Chem (2015) 58:1053-1063.
[cited by applicant]
Roth et al., “Nintedanib: From Discovery to the Clinic,” J. Med. Chem., 2015, 58:1053-1063 (Exhibit No. 1011).
[cited by applicant]
Rúa et al., “Oral Doxycycline Reduces Pterygium Lesions; Results from a Double Blind, Randomized, Placebo Controlled Clinical Trial,” PLOS ONE, Dec. 2012, 7(12):e52696, 7 pages.
[cited by applicant]
Schlunck et al., “Conjunctival fibrosis following filtering glaucoma surgery.”, Exp Eye Res., 142: 76-82, 2016.
[cited by applicant]
Sonoda et al., “ACAID induced by allogeneic corneal tissue promotes subsequent survival of orthotopic corneal grafts.”, Invest Ophthalmol Vis Sci., 41(3): 790-8, 2000.
[cited by applicant]
Sonoda et al., “Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice.”, Invest Ophthalmol Vis Sci., 36(2): 427-34, 1995.
[cited by applicant]
Supplementary European Search Report in EP Appln. No. 17807295, dated Jan. 29, 2020, 7 pages.
[cited by applicant]
Third Party Submission Under 37 CFR 1.290 for U.S. Appl. No. 15/474,620, dated Oct. 20, 2017, 3 pages.
[cited by applicant]
U.S. Appl. No. 62/183,180, filed Jun. 22, 2015, 14 pages.
[cited by applicant]
US Patent Application Publication No. 2008/0003219, published on Jan. 3, 2008, Peyman, 11 pages (Exhibit No. 1021).
[cited by applicant]
US Patent Application Publication No. 2013/0012531, published on Jan. 10, 2013, King et al., 13 pages (Exhibit No. 1008).
[cited by applicant]
U.S. Pat. No. 10,149,820, issued on Dec. 11, 2018, Ni, 20 pages (Exhibit No. 1001).
[cited by applicant]
U.S. Appl. No. 62/172,063, filed Jun. 6, 2015, 18 pages (Exhibit No. 1003).
[cited by applicant]
U.S. Appl. No. 62/183,180, filed Jun. 22, 2015, 24 pages (Exhibit No. 1007).
[cited by applicant]
U.S. Appl. No. 62/186,660, filed Jun. 30, 2015, 20 pages (Exhibit No. 1004).
[cited by applicant]
Van Bergen et al., “Inhibition of placental growth factor improves surgical outcome of glaucoma surgery.”, J Cell Mol Med., 17(12): 1632-43, 2013.
[cited by applicant]
Vandewalle et al., “Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study.”, Br J Ophthalmol., 98(1): 1-6, 2013.
[cited by applicant]
Wollin et al., “Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis,” Eur. Respir. J., 2015, 45(5): 1434-45.
[cited by applicant]
Wong et al., “Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery.”, Invest Ophthalmol Vis Sci., 44(3): 1097-1103, 2003.
[cited by applicant]
Yamagami et al., “The critical role of lymph nodes in corneal alloimmunization and graft rejection.”, Invest Ophthalmol Vis Sci., 42(6): 1293-8, 2001.
[cited by applicant]
Yu et al., “High-risk corneal allografts: A therapeutic challenge.”, World J Transplant., 6(1): 10-27, 2016.
[cited by applicant]
Zhang et al., “Correlation of vascular endothelial growth factor and CD105-microvascular density in primary pterygium,” J Huazhong Univ Sci Technol., 2011, 31(4):560-564.
[cited by applicant]
Qazi et al., “ Corneal allograft rejection: immunopathogenesis to therapeutics,” J. Clin Cell. Immunol., 2013, Suppl 9.
[cited by applicant]
Chen et al., Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling, Oncotarget, 6(17):14940-14952.
[cited by applicant]
Yang et al., “The therapeutics on ophthalmocace of middle and old aged with integration of Chinese and western medicine,” May 31, 2009, 70-71 (with English translation).
[cited by applicant]
[cited by applicant]
Cholkar et al., “Novel Strategies for Anterior Segment Ocular Drug Delivery,” Journal of Ocular Pharmacology and Therapeutics, 2013, 29(2): 106-123.
[cited by applicant]
Morrison et al., “Advances in ophthalmic drug delivery,” Therapeutic Delivery, 5(12):1297-1315.
[cited by applicant]
O'Hare et al., “AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance,” Cancer Cell, Nov. 3, 2009, 16(5):401-412.
[cited by applicant]
Oxford Handbook of Ophthalmology, Oxford University Press, Jan. 2014, Chapter 26, pp. 1003-1021.
[cited by applicant]
Belghmaidi et al., “Management of corneal neovascularization prior to corneal transplantation: Report of 112 cases,” J. Fr. Opthalmol, Jun. 2016, 39(6):515-520 (with English Summary).
[cited by applicant]
Bhatti et al., “Efficacy Of Topical Bevacizumab In High-Risk Corneal Transplant Survival,” Pak J Med Sci., Apr. 2013, 29(2):519-22.
[cited by applicant]
Bock et al., “Bevacizumab As A Potent Inhibitor Of Inflammatory Corneal Angiogenesis And Lymphangiogenesis,” Invest Ophthalmol Vis Sci., Jun. 2007, 48(6):2545-52.
[cited by applicant]
Campos-Mollo et al., “New Corneal Neovascularization Model in Rabbits for Angiogenesis Research,” Ophthalmic Res., Sep. 2010, 45(3): 135-141.
[cited by applicant]
Chang et al., “Corneal Neovascularization: An Anti-VEGF Therapy Review,” Survey of Opthalmol., Sep.-Oct. 2012, 57(5): 415-429.
[cited by applicant]
Cursiefen et al., “Corneal Lymphangiogenesis: Evidence, Mechanisms, And Implications For Corneal Transplant Immunology,” Cornea, Apr. 2003, 22(3):273-81.
[cited by applicant]
Cursiefen et al., “Inhibition Of Hemangiogenesis And Lymphangiogenesis After Normal-Risk Corneal Transplantation By Neutralizing VEGF Promotes Graft Survival,” Investigative Ophthalmology & Visual Science, Aug. 2004, 45…
[cited by applicant]
Cursiefen et al., “VEGF-A Stimulates Lymphangiogenesis And Hemangiogenesis In Inflammatory Neovascularization Via Macrophage Recruitment,” J Clin Invest., Apr. 2004, 113(7): 1040-50.
[cited by applicant]
Detry et al., “Sunitinib Inhibits Inflammatory Corneal Lymphangiogenesis,” Investigative Ophthalmology & Visual Science, May 2013, 54(5):3082-93.
[cited by applicant]
Elhayek et al., “Sustained Release Of Bevacizumab From Hydrogel Depots For Intravitreal Injections,” Investigative Ophthalmology & Visual Science, Apr. 2014, 2 pages.
[cited by applicant]
Fala et al., “Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis,” Am Health Drug Benefits, Special Feature, Mar. 2015, 8:101-104.
[cited by applicant]
Harooni et al., “Letter To The Editor: Bevacizumab For Graft Rejection,” Opthamology, Oct. 2007, 114(10):P1950.
[cited by applicant]
Hos et al., “Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation,” Investigative Opthalmology & Visual Sci…
[cited by applicant]
Jo et al., “Inhibition Of Platelet-Derived Growth Factor B Signaling Enhances The Efficacy Of Anti-Vascular Endothelial Growth Factor Therapy In Multiple Models Of Ocular Neovascularization,” Am J Pathol., Jun. 2006, 16…
[cited by applicant]
Letter of the Proprietor to the EPO in European Appln. No. 17807296.3, mailed on Jul. 20, 2020, 9 pages.
[cited by applicant]
Li et al., “Controlled Release Of Bevacizumab Through Nanospheres For Extended Treatment Of Age-Related Macular Degeneration,” Open Ophthalmol J., Jun. 11, 2012, 6:54-8.
[cited by applicant]
Lin et al., “Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib,” Drug Design, Development and Therapy, Apr. 2017, 11:1147-1158.
[cited by applicant]
Mésange et al., “Intrinsic Bevacizumab Resistance Is Associated With Prolonged Activation Of Autocrine VEGF Signaling And Hypoxia Tolerance In Colorectal Cancer Cells And Can Be Overcome By Nintedanib, A Small Molecule …
[cited by applicant]
nhs.uk [online], “Overview: Cornea Transplant,” Mar. 7, 2024, retrieved on Jun. 3, 2024, retrieved from URL <https://www.nhs.uk/conditions/cornea-transplant/>, 2 pages.
[cited by applicant]
Notice of Opposition in European Appln. No. 17807296.3, mailed on Mar. 19, 2024, 29 pages.
[cited by applicant]
Onder et al., “Inhibitory Effects Of Regorafenib, A Multiple Tyrosine Kinase Inhibitor, On Corneal Neovascularization,” Int J Ophthalmol., Apr. 18, 2014, 7(2):220-5.
[cited by applicant]
Rauck et al., “Biocompatible Reverse Thermal Gel Sustains The Release Of Intravitreal Bevacizumab In Vivo,” Investigative Ophthalmology & Visual Science, Jan. 2014, 55(1):469-476.
[cited by applicant]
Rivera et al., “BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization And Enhances Normal Vascularization In A Model Of Vasoproliferative Retinopathy,” Investigative Ophthalmology & Visual Science, Dec. 2015, 56(13…
[cited by applicant]
Wikipedia.com [online], “Neovascularization,” retrieved on Jun. 3, 2024 retrieved from URL <https://en.wikipedia.org/wiki/Neovascularization#:˜: text=Neovascularization%20is%20the%20natural%20formation,local%20poor%20pe…
[cited by applicant]
Pandey, “Assessment of the Most Common Pterygium Symptoms and Risk Factors Leading to the Decision for its Surgical Removal-A long term study,” Semantic Scholar, Mar. 2017, 4 pages.
[cited by applicant]
Wang et al., “Clinical Observation On Pterygium Excision Combined With Autologous Conjunctiva Transplantation,” Chinese Journal Of Ophthalmology And Otorhinolaryngology, Sep. 25, 2012, 4 pages (with machine translation).
[cited by applicant]
Xu et al., “Recent Advances In Drug Therapy Of Corneal Neovascularization,” Recent Advances In Ophthalmology, Oct. 31, 2015, 989-993, 11 pages (with machine translation).
[cited by applicant]
Cited By (1)